Endothelial progenitor cells in coronary artery disease: from bench to bedside

F Pelliccia, M Zimarino, G De Luca… - Stem Cells …, 2022 - academic.oup.com
Endothelial progenitor cells (EPCs) are a heterogeneous group of cells present in peripheral
blood at various stages of endothelial differentiation. EPCs have been extensively …

Patient-related factors predicting stent thrombosis in percutaneous coronary interventions

L Anghel, BS Tudurachi, A Tudurachi, A Zăvoi… - Journal of Clinical …, 2023 - mdpi.com
Over the past four decades, percutaneous coronary intervention (PCI) safety and efficacy
have significantly improved, particularly with the advent of the drug-eluting stent (DES). First …

Endothelial progenitor cells in coronary atherosclerosis and percutaneous coronary intervention: a systematic review and meta-analysis

F Pelliccia, V Pasceri, M Zimarino, G De Luca… - Cardiovascular …, 2022 - Elsevier
Introduction The role of endothelial progenitor cells (EPCs) in atherosclerosis progression
and neointimal growth after percutaneous coronary intervention (PCI) remains controversial …

[HTML][HTML] Endothelial progenitor cells and coronary artery disease: Current concepts and future research directions

ST **ao, CY Kuang - World journal of clinical cases, 2021 - ncbi.nlm.nih.gov
Vascular injury is a frequent pathology in coronary artery disease. To repair the vasculature,
scientists have found that endothelial progenitor cells (EPCs) have excellent properties …

The bioengineered combo dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent in patients with chronic total occlusion evaluated by clinical outcome …

R Blessing, M Ahoopai, M Geyer, M Brandt… - Journal of clinical …, 2020 - mdpi.com
We sought to determine the effects of the use of a Bioengineered Combo Dual-Therapy
CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent (Combo® DTS) in patients with …